Background: Immune thrombocytopenic purpura (ITP) is an autoimmuneassociated thrombocytopenia which is occasionally the initial presentation of systemic lupus erythematosus (SLE), and thus periodical following up has been suggested. Whereas long-term surveillance on all ITP patients would be time and cost-consuming, and thus to distinguish those with high probability of SLE development among ITP patients should be more practical.
Objectives:
To distinguish ITP patients with high risk of SLE development by a decision tree model. Methods: We enrolled ITP patients without previous SLE diagnosis from the National Health Insurance research database between 1997 and 2012 and identified those certificated with catastrophic illness of SLE during follow up, by which the diagnosis was reconfirmed by another rheumatologists. We also analyzed the symptoms and comorbidities as well as the dose of average oral steroid to derive the decision trees, which classified the ITP patients with different probability of development of SLE. Results: A total of 10,265 ITP patients were enrolled, among whom 80 patients developed SLE while following-up. The whole ITP patients were allocated to training group (7,186 patients including 57 with SLE) and testing group (3,079 patients including 23 with SLE); the former was used for derivation of the decision-tree based model and the latter for validation of the previously mentioned model, and provided high sensitivity (78.2%), specificity (99.2%) and negative prediction value (99.8%, Fig.) . To reduce the complexity, we also pruned our decision tree to propose less-complicated models.
Conclusions:
We derived classification decision tree suitable for various clinical scenarios of ITP patients, among whom those with high probability of development of SLE would be distinguished. Background: Antiphospholipid syndrome has been shown to be associated with increased cardiovascular mortality, but the role of antiphospholipid antibodies (aPL) on endothelial dysfunction remains elusive. Objectives: We investigated the association between endothelial dysfunction and aPL in systemic lupus erythematosus (SLE) patients. Methods: 188 SLE patients and 62 controls were enrolled. Endothelial function was measured by flow-mediated dilatation (FMD). Cardiovascular risk factors were assessed and quarterly measurement of anti-cardiolipin (aCL) and anti-β 2 glycoprotein I Ab were used to calculate time-integrated values throughout disease duration. Circulating endothelial progenitor cell (EPC), defined by CD34+/KDR+ mononuclear cells, was quantified by flow cytometry. Results: Median FMD was significantly lower in SLE patient than in controls (6.9 versus 9.3%, P<0.001). In univariate analysis, older age, hypertension, thrombocytopenia, and persistent positive lupus anticoagulant (LAC) were associated with decreased FMD in SLE patients (P=0.021, P=0.011, P=0.004, and P=0.028). Time-integrated aCL value (TI-aCL), but not a single value, was correlated with decreased FMD (P=0.001). Multivariate analysis showed that hypertension and TI-aCL were independent factors for decreased FMD (P=0.027, P=0.008); addition of positive LAC increased the adjusted probability of decreased FMD (P=0.023). FMD was correlated with EPC number (γ=0.342, P=0.005) and TI-aCL was also an independent factor of reduced EPC after multiple adjustment (P=0.019). The predicted probability of endothelial dysfunction at median EPC level was higher in group with high TI-aCL than in group with low TI-aCL (P=0.004). Conclusions: Cumulative burden of aPL was closely associated with endothelial dysfunction in SLE patients, which was mediated in part by reduction of EPC. Objectives: To analyze the differential expression, regulation and the pathophysiological role of miR-125b in systemic sclerosis (SSc). Methods: For screening a low density array was run on pooled RNA from fibroblasts derived from 3 SSc patients vs. 3 healthy controls (HC). For further validation we performed qPCR on RNA derived from cultured fibroblasts, whole skin biopsies as well as on paraffin fixed dermis and epidermis. Next, fibroblasts were stimulated with pro-inflammatory and/or pro-fibrotic cytokines such as TGFβ, IL-1β, -4, -13, -17A, TNFα and PDGF. In order to identify downstream effects of miR-125b, knockdown with anti-miR-125b (or scrambled controls) in HC fibroblasts was performed. RNA was isolated from healthy fibroblasts (n=4) after knockdown and was proceeded to deep sequencing using Illumina HiSeq2000. Sequencing data were validated using qPCR on HC as well as SSc fibroblasts. Apoptosis was assessed by Caspase-Glo 3/7 assay and immunofluorescence of cleaved caspase 3 on cultured fibroblasts. Results: Screening identified miR-125b as one of the candidate miRs differentially expressed in SSc. MiR-125b was confirmed by qPCR in primary dermal fibroblasts (SSc =11, HC =8), where it was downregulated by 47% (median expression 53%, Q 1,3 33%, 70%; p<0.01). MiR-125b expression appeared to be independent from main cytokines operative in SSc. Additionally, the expression of miR-125b was assessed in skin biopsies of both SSc patients (n=4) and HC (n=5). In SSc, miR-125b was downregulated by 35% (median expression 65%, Q 1,3 61%, 78%; p<0.05). To localize its expression in the skin, we separately analyzed miR-125b expression in dermis and epidermis of paraffin fixed skin. In both cases, expression of miR-125b was downregulated. RNA sequencing identified >3500 differentially expressed genes with p<0.05. More than half of the differently expressed genes with at least 15% change were predicted targets of miR-125b by TargetScan and MiRWalk, indicating successful functional inhibition of miR-125b. Gene ontology revealed extracellular matrix organization and apoptosis regulation as the two main clusters of differentially expressed genes. Among them, BAK1, BMF and BBC3 are participants of the BCL2 apoptosis pathway and predicted targets of miR-125b. Consistent with the sequencing results, qPCR showed that knockdown of miR-125b upregulates these genes 24, 48 and 72 hours after transfection (p<0.05 for each). That was confirmed also on protein level by Western blot. Accordingly, miR-125b knockdown resulted in a higher rate of apoptosis (mean±SD: 60% ± 29%, p<0.01) compared to scrambled controls, measured by Caspase-Glo 3/7 assay. Moreover, miR-125b knockdown reduced TGFβ-induced αSMA expression both on RNA and protein levels, suggesting that miR-125b might play an additional role in the cytoskeletal reorganization of fibroblasts during fibrosis. Conclusions: MiR-125b is differentially expressed in SSc skin and primary dermal fibroblasts. MiR-125b downregulation increases apoptosis, inhibits cytoskeletal reorganization and therefore might become a potential anti-fibrotic therapeutic strategy. 
